Dr. Horwitz on Updates in T-Cell Lymphoma Treatment
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some new treatments on the horizon for T-cell lymphoma.
Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some new treatments on the horizon for T-cell lymphoma.
Horwitz says there is a modest subgroup of patients that respond well to new agents in the relapsed setting. If researchers are able to figure out which of these patients will benefit the most in this subset it will change their prognosis significantly.
Researchers now also have a better understanding of the biology and underlying molecular mechanisms of this disease, Horwitz says. New mutations are also being discovered, which will help researchers develop new targeted agents.
Horwitz says more work needs to be done to determine which patients will benefit from novel agents in order to deliver better outcomes.
​
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
December 2nd 2023The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
